financetom
Business
financetom
/
Business
/
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
Nov 20, 2024 7:41 PM

05:02 PM EST, 11/20/2024 (MT Newswires) -- (Updates the stock change in the last paragraph.)

Nvidia ( NVDA ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.81 per diluted share, up from $0.40 a year earlier.

Analysts polled by FactSet expected $0.75 excluding some items.

Revenue in the three months ended Oct. 27 rose to $35.08 billion from $18.12 billion a year earlier.

Analysts surveyed by FactSet expected $33.17 billion.

The company expects fiscal Q4 revenue of $37.5 billion, plus or minus 2%. Analysts expect $37.09 billion.

Nvidia ( NVDA ) shares fell 0.7% in after-hours activity, paring earlier losses.

Price: 144.81, Change: -1.08, Percent Change: -0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO
BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO
Nov 3, 2024
Oct 30 (Reuters) - Polyrizon Ltd ( PLRZ ): * POLYRIZON ANNOUNCES CLOSING OF $4.2 MILLION INITIAL PUBLIC OFFERING Source text: Further company coverage: ...
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
Nov 3, 2024
11:04 AM EDT, 10/30/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Wednesday it has seen positive interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease. Treatment with the gene therapy candidate resulted in dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive...
Bancfirst Corp Insider Sold Shares Worth $567,500, According to a Recent SEC Filing
Bancfirst Corp Insider Sold Shares Worth $567,500, According to a Recent SEC Filing
Nov 3, 2024
11:08 AM EDT, 10/30/2024 (MT Newswires) -- William Scott Martin, Director, on Oct. 30, 2024, sold 5,000 shares in Bancfirst Corp ( BANF ) for $567,500. Following the Form 4 filing with the SEC, Martin has control over a total of 306,904 shares of the company, with 306,904 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/760498/000159396824001319/xslF345X05/primary_01.xml Price: 112.39, Change: +1.68, Percent Change: +1.52...
Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy
Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy
Nov 3, 2024
11:06 AM EDT, 10/30/2024 (MT Newswires) -- Tharimmune ( THAR ) shares climbed by more than 130% in recent Wednesday trading after the company said it received positive feedback from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC. The feedback came in a Scientific Advice meeting, the company said, where...
Copyright 2023-2026 - www.financetom.com All Rights Reserved